SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

MORARI, Michele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.008
AS - Asia 7.069
EU - Europa 3.925
SA - Sud America 993
AF - Africa 152
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 4
Totale 26.166
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.714
SG - Singapore 2.671
CN - Cina 1.799
VN - Vietnam 861
DE - Germania 794
BR - Brasile 760
UA - Ucraina 638
IT - Italia 551
HK - Hong Kong 505
GB - Regno Unito 466
TR - Turchia 433
FI - Finlandia 415
FR - Francia 261
JP - Giappone 181
SE - Svezia 181
RU - Federazione Russa 158
IN - India 145
CA - Canada 137
MX - Messico 123
PL - Polonia 119
ID - Indonesia 105
BD - Bangladesh 92
AR - Argentina 89
AT - Austria 72
ZA - Sudafrica 61
ES - Italia 55
BE - Belgio 52
NL - Olanda 52
PK - Pakistan 50
IQ - Iraq 47
EC - Ecuador 34
CO - Colombia 30
VE - Venezuela 29
LT - Lituania 28
PH - Filippine 22
MA - Marocco 21
UZ - Uzbekistan 19
SA - Arabia Saudita 18
EG - Egitto 17
MY - Malesia 16
PE - Perù 16
KE - Kenya 15
AE - Emirati Arabi Uniti 13
AU - Australia 13
CL - Cile 13
CZ - Repubblica Ceca 13
JO - Giordania 13
IR - Iran 11
NO - Norvegia 9
BG - Bulgaria 8
BO - Bolivia 8
CH - Svizzera 8
ET - Etiopia 8
IE - Irlanda 8
NP - Nepal 8
PY - Paraguay 8
TN - Tunisia 8
AZ - Azerbaigian 7
DZ - Algeria 7
IL - Israele 7
PA - Panama 7
KG - Kirghizistan 6
KZ - Kazakistan 6
CR - Costa Rica 5
HN - Honduras 5
PS - Palestinian Territory 5
RO - Romania 5
AL - Albania 4
BH - Bahrain 4
JM - Giamaica 4
LV - Lettonia 4
PT - Portogallo 4
TT - Trinidad e Tobago 4
UY - Uruguay 4
BW - Botswana 3
DK - Danimarca 3
HR - Croazia 3
KR - Corea 3
LY - Libia 3
OM - Oman 3
RS - Serbia 3
CG - Congo 2
DM - Dominica 2
DO - Repubblica Dominicana 2
EE - Estonia 2
EU - Europa 2
GE - Georgia 2
GR - Grecia 2
KH - Cambogia 2
LK - Sri Lanka 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
SR - Suriname 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
TW - Taiwan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
Totale 26.147
Salva come PNG Salva come JPEG
Città #
Ashburn 1.835
Singapore 1.749
Fairfield 1.266
Woodbridge 1.234
San Jose 884
Houston 702
Jacksonville 673
Beijing 668
Chandler 666
Santa Clara 592
Ann Arbor 517
Hong Kong 495
Seattle 485
Wilmington 450
Cambridge 415
Munich 365
Dallas 274
Ho Chi Minh City 259
Izmir 239
Helsinki 211
Hanoi 204
Los Angeles 199
New York 180
Tokyo 175
Nanjing 173
Ferrara 168
Princeton 165
Council Bluffs 163
Lauterbourg 131
San Diego 114
Warsaw 109
Boardman 105
Shanghai 105
Milan 90
São Paulo 78
Jakarta 76
London 70
Mexico City 69
Bremen 66
Orem 64
Turku 58
Shenyang 57
Brussels 50
Da Nang 49
Falls Church 48
Montreal 48
The Dalles 48
Tianjin 48
Brooklyn 47
Chicago 46
Hebei 45
Hefei 45
Vienna 45
Buffalo 43
Frankfurt am Main 43
Moscow 43
Atlanta 41
Denver 40
Nanchang 38
Boston 36
Haiphong 35
Toronto 35
Chennai 34
Stockholm 34
Johannesburg 33
Changsha 31
Manchester 31
Jiaxing 29
Norwalk 29
Poplar 29
Biên Hòa 26
Rio de Janeiro 25
San Francisco 25
San Mateo 25
Washington 25
Ankara 24
Auburn Hills 24
Amsterdam 22
Jinan 22
Falkenstein 21
Mountain View 21
Phoenix 21
New Delhi 20
Redwood City 20
Rome 20
Guangzhou 19
Baghdad 18
Belo Horizonte 18
Brasília 18
Mumbai 18
Dearborn 17
Tashkent 17
Zhengzhou 17
Istanbul 16
Nuremberg 16
Querétaro 16
Charlotte 15
Lahore 15
Ottawa 15
Lappeenranta 14
Totale 18.311
Salva come PNG Salva come JPEG
Nome #
[Nphe(1),Arg(14),Lys(15)]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor 391
Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK-21273 in comparison with SB-612111 374
Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity 321
Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists 277
D-Aspartate oxidase influences glutamatergic system homeostasis in mammalian brain 272
[(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor 268
Safinamide differentially modulates in vivo glutamate and GABA release in the rat hippocampus and basal ganglia 263
Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice 261
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease 257
Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior 256
GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats 256
Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels 236
5‐Hydroxytryptamine‐mediated effects of nicotine on endogenous GABA efflux from guinea‐pig cortical slices 233
AMPA receptor activation regulates the glutamate metabotropic receptor stimulated phosphatidylinositol turnover in human cerebral cortex slices 233
Differential involvement of Ras-GRF1 and Ras-GRF2 in L-DOPA-induced dyskinesia 233
G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice 224
Antagonism of metabotropic glutamate receptor type 5 attenuates L-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease 223
Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease 220
Loss of cortical GABA terminals in Unverricht–Lundborg disease 219
Nocistatin inhibits 5-hydroxytryptamine release in the mouse neocortex via presynaptic G i/o protein linked pathways 217
Striatal Dopamine-NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: opposite role for D1 and D2 receptors 217
Pharmacological profile of nociceptin/orphanin FQ receptors regulating 5-hydroxytryptamine release in the mouse neocortex 216
Protein Kinase C β: a New Target Therapy to Prevent the Long-Term Atypical Antipsychotic-Induced Weight Gain 216
Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release 212
Role of LRRK2 in the regulation of dopamine receptor trafficking 212
In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels 212
Dopamine-nociceptin/orphanin FQ interactions in the substantia nigra reticulata of hemiparkinsonian rats: Involvement of D2/D3 receptors and impact on nigro-thalamic neurons and motor activity 211
Changes of glutamatergic control of striatal acetylcholine release in experimental parkinsonism 211
Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging 211
Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl] methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: In vitro studies 211
Antagonisti dei recettori NOP e loro usi terapeutici 210
Alpha-2 adrenoreceptor-mediated decrease in gamma-aminobutyric acid outflow in cortical slices and synaptosomes during morphine tolerance 210
Leucine-rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes 210
Autophagy and LRRK2 in the Aging Brain 210
Genetic deletion of Rhes or pharmacological blockade of mTORC1 prevent striato-nigral neurons activation in levodopa-induced dyskinesia 209
Differential responsiveness of rat striatal nerve endings to the mitochondrial toxin 3-nitropropionic acid: implications for Huntington’s disease 207
Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease 206
Loss of the preferential control over the striato-nigral direct pathway by striatal NMDA receptors in a rat model of Parkinson's disease 203
Striatal glutamate release evoked in vivo by NMDA is dependent upon ongoing neuronal activity in the substantia nigra, endogenous striatal substance P and dopamine 202
Pharmacological profiles of presynaptic nociceptin/orphanin FQ receptors modulating 5-hydroxytryptamine and noradrenaline release in the rat neocortex 200
NR2B subunit blockade does not affect motor symptoms induced by 3-nitropropionic acid 199
Differential effect of NR2A and NR2B subunit selective NMDA receptor antagonists on striato-pallidal neurons: relationship to motor response in the 6-hydroxydopamine model of parkinsonism 198
NOP receptor ligands and Parkinson’s disease 198
Plasticity of glutamatergic control of striatal acetylcholine release in experimental parkinsonism: opposite changes at group-II metabotropic and NMDA receptors 197
Effect of acute and subchronic nicotine treatment on cortical efflux of [3H]‐d‐aspartate and endogenous GABA in freely moving guinea‐pigs 197
Mitochondrial P2X7 Receptor Localization Modulates Energy Metabolism Enhancing Physical Performance 197
Nanoparticulate lipid dispersions for bromocriptine delivery: characterization and in vivo study 195
Pharmacological and genetic evidence for pre- and postsynaptic D2 receptor involvement in motor responses to nociceptin/orphanin FQ receptor ligands 194
Olanzapine, but not clozapine, increases glutamate release in the prefrontal cortex of freely moving mice by inhibiting D-aspartate oxidase activity 194
Lipid nanocarriers containing a Levodopa prodrug with potential antiparkinsonian activity 193
Progressive Motor Cortex Functional Reorganization Following 6-Hydroxydopamine Lesioning in Rats 192
Nociceptin/Orphanin FQ Inhibits the Survival and Axon Growth of Midbrain Dopaminergic Neurons Through a p38-MAPK Dependent Mechanism 188
Selectivity and Anti-Parkinsons Potential of Thiadiazolidinone RGS4 Inhibitors 187
Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release 187
Increased responsivity of glutamate release from the substantia nigra pars reticulata to striatal NMDA receptor blockade in a model of Parkinson's disease. A dual probe microdialysis study in hemiparkinsonian rats 186
The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway 185
NMDA and non-NMDA ionotropic glutamate receptors modulate striatal acetylcholine release via pre- and postsynaptic mechanisms 184
Direct and indirect inhibition by nociceptin/orphanin FQ on noradrenaline release from rodent cerebral cortex in vitro 184
Stimulation of Delta Opioid Receptor and Blockade of Nociceptin/Orphanin FQ Receptor Synergistically Attenuate Parkinsonism 183
Agonisti dei recettori NOP per il trattamento delle discinesie da levodopa; 182
Leucine-rich repeat kinase 2 controls protein kinase A activation state through phosphodiesterase 4 181
Differential role of striatal and nigral D1receptors in the expression of L-DOPA induced dyskinesia and its neurochemical correlates 180
Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease 179
Nanostructured lipid carriers as delivery systems for parkinson’s therapy 178
Glutamate antagonists prevent morphine withdrawal in mice and guinea pigs 178
Functional neuroanatomy of the nigrostriatal and striatonigral pathways as studied with dual probe microdialysis in the awake rat - I. Effects of perfusion with tetrodotoxin and low-calcium medium 175
Nociceptin/Orphanin FQ Receptor Agonists Attenuate L-DOPA-Induced Dyskinesias 174
Evidence for a striatal NMDA receptor modulation of nigral glutamate release. A dual probe microdialysis study in the awake freely moving rat 170
Effect of (-)nicotine on GABA efflux from guinea pig cerebral cortex slices. 170
Parkinson's disease: no NOP, new hope 170
Excitatory amino acids (EAAs) stimulate phosphatidylinositol turnover in adult rat striatal slices: interaction between NMDA and EAA metabotropic receptors. 166
Managing Parkinson's disease: moving ON with NOP 166
Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease 166
Presynaptic group I and II metabotropic glutamate receptors oppositely modulate striatal acetylcholine release 163
Novel therapeutic strategies for treatment of motor abnormalities in Parkinson’s disease: focus on opioid receptors 161
L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum 160
Inhibitory effect of NMDA receptor activation on quisqualate-stimulated phosphatidylinositol turnover in the human cerebral cortex 159
Nociceptin/orphanin FQ receptors modulate glutamate extracellular levels in the substantia nigra pars reticulata. A microdialysis study in the awake freely moving rat 157
Gene Co-expression Analysis Identifies Histone Deacetylase 5 and 9 Expression in Midbrain Dopamine Neurons and as Regulators of Neurite Growth via Bone Morphogenetic Protein Signaling 157
6-Hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulata 156
Nociceptin/orphanin FQ receptor antagonists riverse akinesia in rat parkinsonian models 155
Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease 155
In vivo susceptibility to energy failure parkinsonism and LRRK2 kinase activity 154
L-DOPA-induced modulation of GABA and glutamate release in the substantia nigra pars reticulata and globus pallidus in a rat model of dyskinesia 153
Nociceptin/orphanin FQ receptors modulate locomotion and motor cortex excitability in adult Rats 151
Discovery and Structure-Activity Relationships of Nociceptin Receptor Partial Agonists That Afford Symptom Ablation in Parkinson's Disease Models 151
Evidence for a protective action of the vigilance promoting drug modafinil on the MPTP-induced degeneration of the nigrostriatal dopamine neurons in the black mouse: an immunocytochemical and biochemical analysis 149
L-DOPA promotes striatal dopamine release through D1 receptors and reversal of dopamine transporter 149
Dopamine Transporter, PhosphoSerine129 α-Synuclein and α-Synuclein Levels in Aged LRRK2 G2019S Knock-In and Knock-Out Mice 147
Nociceptin/orphanin FQ and neurotransmitter release in the central nervous system 146
Molecular and imaging prodromal markers of dopamine neuron degeneration in animal models of Parkinson’s disease: pathophysiology and clinical perspectives 146
Physiopathological aspects of NMDA transmission in the basal ganglia. In vitro and in vivo release studies 145
Nociceptin/orphanin FQ receptor antagonists reverse parkinsonism in MPTP-treated mice and non-human primates 143
L-glutamate and gamma-aminobutyric acid efflux from rat cerebrocortical synaptosomes: Modulation by kappa- and mu- but not delta- and opioid receptor like-1 receptors 141
Brain interstitial nociceptin/orphanin FQ levels are elevated in Parkinson’s disease 140
Metabotropic glutamate 2 receptors modulate synaptic inputs and calcium signals in striatal cholinergic interneurons 140
Synthesis and structure activity relationships of delthorphine analogues 139
Nociceptin/orphanin FQ receptor antagonists as a novel therapeutic approach to Parkinson’s disease: interaction with levodopa 139
Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia 139
Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats 139
Totale 19.537
Salva come PNG Salva come JPEG
Categoria #
all - tutte 112.941
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.357
Totale 115.298
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021665 0 0 0 0 0 0 0 0 0 262 264 139
2021/20221.562 53 169 130 70 81 95 98 87 55 117 153 454
2022/20231.619 170 132 75 181 263 218 72 124 224 4 101 55
2023/2024803 84 103 39 23 76 135 34 63 24 19 9 194
2024/20253.708 74 88 310 82 402 505 146 204 569 373 528 427
2025/202610.131 1.178 343 893 1.354 1.681 739 1.415 556 979 993 0 0
Totale 26.383